Toward establishing guidelines for evaluating cognitive enhancement with complementary and alterative medicines

Evaluation and the Health Professions

Volumn 32, Issue 4, 2009, Pages 370-392

  Solomon, Paul R ^a,b   Michalczuk, Diana E ^b,c  

^a WILLIAMS COLLEGE   (United States)

^b Memory Clinic   (United States)

^c MIDWESTERN UNIVERSITY   (United States)

Author keywords

Cognition; Complementary medicines; Ginkgo Biloba; Guidelines

Indexed keywords

AGED; ALTERNATIVE MEDICINE; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HUMAN; METHODOLOGY; PRACTICE GUIDELINE; STANDARD; UNITED STATES;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COGNITION DISORDERS; COMPLEMENTARY THERAPIES; EVIDENCE-BASED MEDICINE; GUIDELINES AS TOPIC; HUMANS; RESEARCH DESIGN; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 71549122342     PISSN: 01632787     EISSN: 15523918     Source Type: Journal    
DOI: 10.1177/0163278709346816     Document Type: Article

References (24)

1. Birks, J., & Grimley Evans, J. (2009). Ginkgo biloba for cognitive impairment and dementia. Cochrane Database of Systematic Reviews, 1, 1-150.
2. Burns, N.R., Bryan, J., & Nettelbeck, T. (2006). Ginkgo biloba: No robust effect on cognitive abilities or mood in healthy young or older adults. Human Psychopharmacology: Clinical and Experimental, 21, 27-37.
3. Canter, P.H., & Ernst, E. (2007). Ginkgo biloba is not a smart drug: An updated systematic review of randomized clinical trials testing the nootropic effects of G. biloba extracts in healthy people. Human Psychopharmacology, 22, 265-278.
4. DeKosky, S.T., Williamson, J.D., Fitzpatrick, A.L., Kronmal, R.A., Ives, D.G., Saxton, J.A.,et al.(2008). Ginkgo biloba for prevention of dementia. Journal of the American Medical Association, 300, 2253-2262.
5. Dodge, H.H., Zitzelberger, T., Oken, B.S., Howieson, D., & Kaye, J. (2008). A randomized placebo-controlled trial of Ginkgo biloba for the prevention of cognitive decline. Neurology, 70, 1809-1817.
6. European Medicines Agency. (2008). Pre-authorisation evaluation of medicines for human use. Doc. Ref. CPMP/EWP/553/95 Rev. 1. Retrieved on April 21, 2009, from http://www.emea.europa.eu.
7. Harrison, J., Minassian, S.L., Jenkins, L., Black, R.S., Koller, M., & Grundman, M. (2007). A Neuropsychological test battery for use in Alzheimer disease clinical trials. Archives of Neurology, 64, 1323-1329.
8. Kanowski, S., Herrmann, W.M., Stephan, K., Wierich, W., & Horr, R. (1996). Proof of efficacy of the Ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry, 29, 47-56.
9. Knapp, M.J., Knopman, D.S., Solomon, P.R., Pendlebury, W.W., Davis, C.S., & Gracon, S.I. (1994). A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The tacrine study group. Journal of the American Medical Association, 271, 985-991.
10. Knopman, D.S., Knapp, M.J., Gracon, S.I., & Davis, C.S. (1994). The clinician interview-based impression (CIBI): A clinician's global change rating scale in Alzheimer's disease. Neurology, 44, 2315-2321.
11. Le Bars, P.L., Katz, M.M., Berman, N., Itil, T.M., Freedman, A.M., & Schatzberg, A.F. (1997). A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. Journal of the American Medical Association, 278, 1327-1332.
12. Leber, P. (1990). Guidelines for the evaluation of antidementia drugs (first draft). Rockville, MD: US Food and Drug Administration.
13. Leber, P. (1991, November). Unpublished letter to pharmaceutical companies [Issues affecting the implementation of the Clinician's Global Assessment].
14. Maurer, K., Ihl, R., Dierks, T., & Frolich, L. (1997). Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type. Journal of Psychiatric Research, 31, 645-655.
15. McCarney, R., Fisher, P., Iliffe, S., van Haselen, R., Griffin, M., van der Meulen, J.,et al.(2008). Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomized, parallel-group, double-blind, placebo-controlled trial. International Journal of Geriatric Psychiatry, 23, 1222-1230.
16. Mix, J.A. & Crews Jr., W.D. (2002). A double-blind, placebo-controlled, randomized trial of Ginkgo biloba extract EGb 761 in a sample of cognitively intact older adults: neuropsychological findings. Human Psychopharmacology,17, 267-277.
17. Nathan, P.J., Ricketts, E., Wesnes, K., Mrazek, L., Greville, W., & Stough, C. (2002). The acute nootropic effects of Ginkgo biloba in healthy older human subjects: a preliminary investigation. Human Psychopharmacology: Clinical and Experimental, 17, 45-49.
18. Oken, B.S., Storzbach, D.M., & Kaye, J.A. (1998). The efficacy of Ginkgo biloba on cognitive function in Alzheimer Disease. Archives of Neurology, 55, 1409-1415.
19. Schneider, L.S., DeKosky, S.T., Farlow, M.R., Tariot, P.N., Hoerr, R., & Kieser, M. (2005). A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type. Current Alzheimer Research, 2, 541-551.
20. Scholey, A., Kennedy, D., & Wesnes, K. (2005). The psychopharmacology of herbal extracts: issues and challenges. Psychopharmacology, 179, 705-707.
21. Solomon, P.R. (2003). Contradictory results from 6-week trials of Ginkgo biloba for cognitive performance in healthy older subjects. Focus on Alternative and Complementary Therapies, 8, 21-61.
22. Solomon, P.R. (2005). Response to "The psychopharmacology of herbal extracts: issues and challenges." Psychopharmacology, 179, 710-711.
23. Solomon, P.R., Adams, F., Silver, A., Zimmer, J., & DeVeaux, R. (2002). Ginkgo for memory enhancement: A randomized controlled trial. Journal of the American Medical Association, 288, 835-840.
24. Wesnes, K., Simmons, D., Rook, M., & Simpson, P. (1987). A double-blind placebo controlled trial of Tanakan in the treatment of idiopathic cognitive impairment in the elderly. Human Psychopharmacology, 2, 159-169.